VEGFA, FLT1, KDR and colorectal cancer: Assessment of disease risk, tumor molecular phenotype, and survival

Molecular Carcinogenesis

Volumn 53, Issue S1, 2014, Pages

  Slattery, Martha L ^a   Lundgreen, Abbie ^a   Wolff, Roger K ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Aspirin; BMI; Cigarette; CIMP; Colon cancer; Colorectal cancer; Diet; FLT1; KDR; Oxidative balance; Rectal cancer; TP53; VEGFA

Indexed keywords

ASPIRIN; BMI; CIGARETTE; CIMP; COLON CANCER; COLORECTAL CANCER; DIET; FLT1; KDR; OXIDATIVE BALANCE; RECTAL CANCER; TP53; VEGFA;

ADULT; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; UTAH; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84894467305     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22058     Document Type: Article

References (36)

1. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011; 2:1097-1105.
2. Shibuya M. Tyrosine kinase receptor Flt/VEGFR family: Its characterization related to angiogenesis and cancer. Genes Cancer 2010; 1:1119-1123.
3. Waldner MJ, Wirtz S, Jefremow A, et al. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 2010; 207:2855-2868.
4. Yoo SA, Kwok SK, Kim WU. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: Prospects for therapeutic intervention. Mediators Inflamm 2008; 2008:129873.
5. Prager GW, Poettler M. Angiogenesis in cancer. Basic mechanisms and therapeutic advances. Hamostaseologie 2012; 32:105-114.
6. Hu K, Zhang Y, Wang R, Li G, Zhang D. Current evidence on VEGF+405G/C polymorphism and malignancy susceptibility: A meta-analysis involving 30 studies. Twin Res Hum Genet 2012; 15:496-502.
7. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer-Beyond physical activity. Cancer Res 1997; 57:75-80.
8. Slattery ML, Edwards S, Curtin K, et al. Physical activity and colorectal cancer. Am J Epidemiol 2003; 158:214-224.
9. Edwards S, Slattery ML, Mori M, et al. Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 1994; 140:1020-1028.
10. Liu K, Slattery M, Jacobs D Jr, et al. A study of the reliability and comparative validity of the cardia dietary history. Ethn Dis 1994; 4:15-27.
11. Slattery ML, Caan BJ, Duncan D, Berry TD, Coates A, Kerber R. A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc 1994; 94:761-766.
12. Samowitz WS, Curtin K, Ma KN, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002; 99:597-602.
13. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000; 92:1831-1836.
14. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9:1193-1197.
15. Slattery ML, Curtin K, Sweeney C, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 2007; 120:656-663.
16. Slattery ML, Curtin K, Wolff RK, et al. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum 2009; 52:1304-1311.
17. Yoon JH, Choi YJ, Lee SG. Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells. Eur J Pharmacol 2012; 679:24-33.
18. Slattery ML, Lundgreen A, Welbourn B, Wolff RK, Corcoran C. Oxidative balance and colon and rectal cancer: Interaction of lifestyle factors and genes. Mutat Res 2012; 734:30-40.
19. Yu K, Li Q, Bergen AW, Pheiffer RM, Rosenberg PS, Caporaso N, Kraft P, Chatterjee N. Genetic Epidemiology 2009; 33:700-709.
20. Shibuya M, Seetharam L, Ishii Y, et al. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis. Princess Takamatsu Symp 1994; 24:162-170.
21. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003; 106:468-471.
22. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37:443-448.
23. Cacev T, Loncar B, Seiwerth S, Spaventi S, Kapitanovic S. Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol 2008; 27:569-574.
24. Park HM, Hong SH, Kim JW, et al. Gender-specific association of the VEGF -2578C>A polymorphism in Korean patients with colon cancer. Anticancer Res 2007; 27:2535-2539.
25. Fujisawa T, Watanabe J, Kamata Y, Hamano M, Hata H, Kuramoto H. Effect of p53 gene transfection on vascular endothelial growth factor expression in endometrial cancer cells. Exp Mol Pathol 2003; 74:276-281.
26. Wendum D, Boelle PY, Rigau V, et al. Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression. Virchows Archiv 2003; 442:111-117.
27. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027.
28. Lurje G, Hendifar AE, Schultheis AM, et al. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics 2009; 19:95-102.
29. Vaish V, Sanyal SN. Role of sulindac and celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/beta-catenin signaling. Biomed Pharmacother 2012; 66:354-367.
30. Wang L, Chen W, Xie X, He Y, Bai X. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp Oncol 2008; 30:42-51.
31. Ouyang N, Williams JL, Rigas B. NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts. Carcinogenesis 2008; 29:1794-1798.
32. Goodman M, Bostick RM, Gross M, Thyagarajan B, Dash C, Flanders WD. Combined measure of pro- and anti-oxidant exposures in relation to prostate cancer and colorectal adenoma risk: An update. Ann Epidemiol 2010; 20:955-957.
33. Goodman M, Bostick RM, Dash C, Terry P, Flanders WD, Mandel J. A summary measure of pro- and anti-oxidant exposures and risk of incident, sporadic, colorectal adenomas. Cancer Causes Control 2008; 19:1051-1064.
34. Fernandez-Robredo P, Recalde S, Arnaiz G, et al. Effect of zeaxanthin and antioxidant supplementation on vascular endothelial growth factor (VEGF) expression in apolipoprotein-E deficient mice. Curr Eye Res 2009; 34:543-552.
35. Rodriguez JA, Nespereira B, Perez-Ilzarbe M, Eguinoa E, Paramo JA. Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL. Cardiovasc Res 2005; 65:665-673.
36. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001; 10:917-923.